Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base

Slides:

Advertisements

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Advertisements

Usman Ahmad, MD, Zuoheng Wang, PhD, Ayesha S

Elizabeth A. David, MD, David T

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Daniel C. Thomas, MD, MPH, Brian N. Arnold, MD, Jessica R

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Roland Assi, MD, MMS, Daniel J. Wong, MD, Daniel J. Boffa, MD, Frank C

Prediction of Long-Term Survival After Lung Cancer Surgery for Elderly Patients in The Society of Thoracic Surgeons General Thoracic Surgery Database

Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database Daniel J. Boffa,

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,

Joshua E. Rosen, BASc, Hari B

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Ravi Rajaram, MD, MSc, Jennifer L

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma Jeeyun Lee, MD, Kyoung-Eun.

Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis Andrew J. Graham, MD, MS, Fiona M. Shrive,

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients Elizabeth A. David, MD, Stina W. Andersen, PhD,

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Joshua E. Rosen, BASc, Michelle C

Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease Brendon M. Stiles, MD, Farooq Mirza, MD, Anthony Coppolino, MD, Jeffrey L. Port,

Brendon M. Stiles, MD, Farooq Mirza, MD, Jeffrey L. Port, MD, Paul C

Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer Justin A. Drake, MD, David C. Portnoy, MD, Kurt.

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Chris Dickhoff, MD, Max Dahele, MD, PhD, Sayed M

Positron Emission Tomography-Computed Tomography for Postoperative Surveillance in Non-Small Cell Lung Cancer Se Hoon Choi, MD, Young Tae Kim, MD, PhD,

Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma:

Diagnosis and Surgical Outcomes for Primary Malignant Melanoma of the Esophagus: A Single-Center Experience Shaohua Wang, MD, Yuji Tachimori, MD, Nobukazu.

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Joshua E. Rosen, BASc, Jacquelyn G. Hancock, BS, Anthony W

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

Characteristics Associated With the Use of Nonanatomic Resections Among Medicare Patients Undergoing Resections of Early-Stage Lung Cancer Anthony W.

Use of Amiodarone After Major Lung Resection

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Abel Gómez-Caro, MD, Pedro Arguis, MD The Annals of Thoracic Surgery

Prognostic Significance of Surgical-Pathologic N1 Lymph Node Involvement in Non- Small Cell Lung Cancer Adalet Demir, MD, Akif Turna, MD, PhD, FETCS,

Number of Lymph Nodes Associated With Maximal Reduction of Long-Term Mortality Risk in Pathologic Node-Negative Non–Small Cell Lung Cancer Raymond U.

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Survival After Surgical Resection of Stage IV Esophageal Cancer

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Daniel C. Thomas, MD, MPH, Justin D. Blasberg, MD, Brian N

Brendon M. Stiles, MD, Mohamed K. Kamel, MD, Sebron W

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Matthew J. Bott, MD, Hanghang Wang, BA, William Travis, MD, Gregory J

Surgical Therapy for Bilateral Multiple Primary Lung Cancer

Selective Mediastinal Lymphadenectomy for Clinico-Surgical Stage I Non–Small Cell Lung Cancer Morihito Okada, MD, PhD, Toshihiko Sakamoto, MD, PhD, Tsuyoshi.

Jonathan D. Spicer, MD, PhD, Jitesh B. Shewale, BDS, PhD, David B

Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: Management of Locoregional Recurrence Michael Lanuti, MD, Amita Sharma, MD, Henning Willers,

Preoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection Emilie Perrot, MD, Benoit Guibert, MD, Pierre Mulsant,

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Vacuum-Assisted Closure for the Treatment of Complex Chest Wounds

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Does Timing of Surgical Procedure After Neoadjuvant Chemoradiation Affect Outcomes in Esophageal Cancer? Williams Tessier, MD, Caroline Gronnier, MD,

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Anna Lee, MD, MPH, Andrew T.

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Benny Weksler, MD, Manisha Shende, MD, Katie S

Pneumonectomy After Chemoradiation Therapy for Non-Small Cell Lung Cancer: Does “Side” Really Matter? Anthony W. Kim, MD, L. Penfield Faber, MD, William.

Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma Po-Kuei Hsu, MD, Chien-Sheng Huang, MD,

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Lobectomy Versus Limited Resection in T1N0 Lung Cancer

The Impact of New Technology on Cardiothoracic Surgical Practice

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Presentation transcript:

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base Amy C. Moreno, BA, Daniel Morgensztern, MD, Daniel J. Boffa, MD, Roy H. Decker, MD, PhD, James B. Yu, MD, Frank C. Detterbeck, MD, Zuoheng Wang, PhD, Michal G. Rose, MD, Anthony W. Kim, MD The Annals of Thoracic Surgery Volume 97, Issue 4, Pages 1149-1155 (April 2014) DOI: 10.1016/j.athoracsur.2013.12.045 Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Overall survival estimates for overall cohort stratified by type of primary therapy. (NST = nonsurgical therapy; PST = primary surgical therapy.) The Annals of Thoracic Surgery 2014 97, 1149-1155DOI: (10.1016/j.athoracsur.2013.12.045) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Overall survival estimates for (A) nonsurgical therapy and (B) primary surgical therapy cohorts stratified by type of therapy. (C-S = neoadjuvant chemotherapy + surgery; CxR = chemoradiation; CxR-S = neoadjuvant chemoradiation + surgery; RT = radiation therapy; S = surgery; S-C = surgery + adjuvant chemotherapy; S-CxR = surgery + adjuvant chemoradiation; S-PORT = surgery + postoperative radiation therapy.) The Annals of Thoracic Surgery 2014 97, 1149-1155DOI: (10.1016/j.athoracsur.2013.12.045) Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions